Related references
Note: Only part of the references are listed.Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
N. Vande Casteele et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment
N. Vande Casteele et al.
GUT (2012)
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease
Benjamin Pariente et al.
INFLAMMATORY BOWEL DISEASES (2012)
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response
Lior Katz et al.
INFLAMMATORY BOWEL DISEASES (2012)
Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
Casper Steenholdt et al.
INFLAMMATORY BOWEL DISEASES (2012)
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Shui-Long Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay
N. Vande Casteele et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
Jean Frederic Colombel et al.
GASTROENTEROLOGY (2011)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Emilie Ducourau et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
G. M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez et al.
JOURNAL OF CROHNS & COLITIS (2010)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Activation of natural regulatory T cells by IgG Fc-derived peptide Tregitopes
Anne S. De Groot et al.
BLOOD (2008)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
GJ Wolbink et al.
ARTHRITIS AND RHEUMATISM (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
AB Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
